Ellevest Inc’s Larimar Therapeutics LRMR Stock Holding History

Ellevest Inc’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-18,828	Closed	-$60.8K	–	445
2025 Q3	$60.8K	Buy	+18,828	New	+$70.6K	0.01%	425

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ellevest Inc's LRMR Position: Q4 2025 in Review

Ellevest Inc sold out of Larimar Therapeutics (LRMR) in Q4 2025, closing a stake of 18,828 shares — an estimated $60.8K sold.

Ellevest Inc first reported a position in LRMR in Q3 2025 and held it in 1 quarter. The position peaked at $60.8K in Q3 2025. 136 funds tracked by Wall St. Rank hold LRMR as of Q4 2025.

Ellevest Inc reported no remaining Larimar Therapeutics position as of Q4 2025 after selling out during the quarter.
Ellevest Inc sold 18,828 Larimar Therapeutics shares in Q4 2025, an estimated $60.8K.
Ellevest Inc first reported a position in Larimar Therapeutics in Q3 2025 and held it in 1 quarter.
Ellevest Inc's Larimar Therapeutics position peaked at $60.8K in Q3 2025.
136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2025.

Based on Ellevest Inc's 13F filing for Q4 2025, filed 10 Feb 2026.